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ABSTRACT
Background Poor health status has been associated
with morbidity and mortality in patients with COPD. To
date, the impact of changes in health status on these
outcomes remains unknown.
Aims To explore the relationship of clinically relevant
changes in health status with exacerbation,
hospitalisation or death in patients with COPD.
Methods Characteristics and health status (St George’s
Respiratory Questionnaire, SGRQ) were assessed over a
period of 3 years in 2138 patients with COPD enrolled
in the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study:
a longitudinal, prospective, observational study.
Associations between change in health status (=4 units
in SGRQ score) during year 1 and time to ﬁrst
exacerbation, hospitalisation and death during 2-year
follow-up were assessed using Kaplan–Meier plots and
log-rank test.
Results 1832 (85.7%) patients (age 63.4±7.0 years,
65.4% male, FEV1 48.7±15.6% predicted) underwent
assessment at baseline and 1 year. Compared with those
who deteriorated, patients with improved or stable
health status in year 1 have a lower likelihood of
exacerbation (HR 0.78 (95% CI 0.67 to 0.89), p<0.001
and 0.84 (0.73 to 0.97), p=0.016, respectively),
hospitalisation (0.72 (0.58 to 0.90), p=0.004 and 0.77
(0.62 to 0.96), p=0.023, respectively) or dying (0.61
(0.39 to 0.95), p=0.027 and 0.58 (0.37 to 0.92),
p=0.019, respectively) during 2-year follow-up. This
effect persisted after stratiﬁcation for age and the
number of exacerbations and hospitalisations during the
ﬁrst year of the study.
Conclusions Patients with stable or improved health
status during year 1 of ECLIPSE had a lower likelihood of
exacerbation, hospitalisation or dying during 2-year
follow-up. Interventions that stabilise and improve health
status may also improve outcomes in patients with COPD.
Trial registration number NCT00292552, registered
at ClinicalTrials.gov.
INTRODUCTION
Patients with COPD have impaired disease-speciﬁc
health status1 2 that may deteriorate over time.3
The St George’s Respiratory Questionnaire (SGRQ)
is a disease-speciﬁc health status questionnaire
reﬂecting a broad variety of health impacts in
patients with chronic respiratory diseases.4 High
baseline SGRQ total scores (ie, poor health status)
have been associated with an increased number of
exacerbations and hospitalisations in patients with
COPD.5 Moreover, higher baseline SGRQ scores
were associated with worse survival.6
An increase of four points or more in SGRQ
total score can be considered as a meaningful wor-
sening of patient’s health status.7 To date, it
remains unknown whether and to what extent clin-
ically relevant changes in disease-speciﬁc health
status may affect morbidity and mortality in
patients with COPD. Nevertheless, it seems reason-
able to hypothesise that a worsening of disease-
speciﬁc health status will be associated with wor-
sening of other important health outcomes.
We sought to explore the impact of clinically rele-
vant 1-year changes in SGRQ total scores on the
likelihood of having an exacerbation, hospitalisation
or dying in patients with COPD, using data from
the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study.8
METHODS
The ECLIPSE study is a multicentre, longitudinal,
prospective 3-year observational study to identify
Key messages
What is the key question?
▸ Whether and to what extent do clinically
relevant changes in health status affect
morbidity and mortality in patients with COPD?
What is the bottom line?
▸ Patients with a 1-year improvement or stable
health status had a lower likelihood of having
an exacerbation, COPD-related hospitalisation
or dying during 2-year follow-up compared
with those whose health status deteriorated.
Why read on?
▸ The current study supports the concept of
routine monitoring health status and suggests
improving or at least stabilising health status in
patients with COPD.
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novel endpoints in COPD.8 Participants were eligible if they
were 40–75 years of age, had a smoking history of 10 or more
pack-years and a diagnosis of COPD conﬁrmed with post-
bronchodilator FEV1/FVC<0.7. Demographic and clinical
characteristics were assessed as described before.9
Health status
Disease-speciﬁc health status was assessed using the COPD-
speciﬁc version of the SGRQ (SGRQ-C) to provide SGRQ
scores. The SGRQ-C has three domain scores (symptoms, activ-
ity and impact) and a total score, ranging from 0 (optimal) to
100 points (worst).4 Health status was assessed at baseline, 1, 2
and 3 years. A change of four units in total score is considered
as the minimum clinically important difference.10 Only the
SGRQ total scores are analysed here.
Study outcomes
Following the initial period of SGRQ total score change deter-
mination, during year 1, the following outcomes were deter-
mined: survival (=all-cause mortality), time to ﬁrst moderate to
severe exacerbation and time to ﬁrst COPD hospitalisation.
Exacerbations were deﬁned as events diagnosed by a clinician
that led to the prescription of antibiotics and/or corticosteroids
and/or to hospitalisation, as described elsewhere.11
Hospitalisations were limited to severe exacerbations requiring
hospital admissions. In ECLIPSE, adverse outcomes were
assessed at each visit plus monthly phone calls.8
Statistics
Categorical variables were described as frequencies. Continuous
variables were tested for normality and were described as mean
and SD. Only patients who had complete SGRQ data at baseline
and at 1-year follow-up were included in the current analyses.
To compare baseline characteristics between patients who com-
pleted the ﬁrst year and those who dropped out during that
time, an independent sample t test or Mann–Whitney U test
was used. Further, baseline characteristics were compared
between patients with a clinically signiﬁcant 1-year deterioration
in SGRQ score (Δ≥+4 points), non-clinically signiﬁcant 1-year
change in SGRQ score (Δ −3.99 to +3.99 points), or a clinically
signiﬁcant 1-year improvement in SGRQ score (Δ≤−4 points).
Continuous variables were compared using a univariate analysis
of variance followed by post hoc least signiﬁcance difference
multiple comparisons or Kruskal–Wallis test followed by Mann–
Whitney U test, as appropriate. Categorical variables were com-
pared using χ2 tests.
For the study outcomes, events were ﬂagged and time to
event observed over a period of 2 years starting after the 1-year
assessment. End of observation time was set at day 1060.
Kaplan–Meier plots illustrate a relationship between 1-year
change in SGRQ score and study outcomes. Interactions
between variables were tested and Kaplan–Meier curves were
constructed for the whole group and further stratiﬁed by
median baseline age (>64 vs ≤64 years) and number of exacer-
bations (<2 vs ≥2 exacerbations) and hospitalisations (<1 vs ≥1
hospitalisations) during the ﬁrst year of the study. HRs, accom-
panied with 95% CIs, represent the ratio of the hazard rates
derived from unadjusted survival analysis. The log-rank test was
used for pairwise comparisons between groups.
Kaplan–Meier curves were constructed using GraphPad
Prism 5. Statistical analyses were performed using IBM SPSS
statistics, V.19.0.
RESULTS
Baseline characteristics
A total of 2138 patients with COPD participated in the
ECLIPSE study, of whom 1832 (85.7%) underwent the 1-year
assessment. They were mostly men, slightly overweight, had a
moderate to severe airﬂow limitation, an impaired exercise cap-
acity, and an impaired health status (table 1). Symptoms of dys-
pnoea, depression or fatigue occurred in 52.0%, 25.3% and
73.7% of patients, respectively.
Patients who completed the 1-year assessment had a signiﬁ-
cantly better baseline lung function, 6-min walk distance
(6MWD), health status and less symptoms compared with those
who dropped out during the ﬁrst year (n=306, table 1).
One-year change in health status
Patients with a 1-year improvement in health status (n=675,
36.8%) had a worse baseline health status compared with those
who remained stable or deteriorated (n=630 and n=527, respect-
ively; table 2). Age, baseline lung function, 6MWD, modiﬁed
Medical Research Council (mMRC) dyspnoea grades, depression
scores and fatigue scores were comparable between groups.
Exacerbations, hospitalisations and mortality
During the 2-year follow-up period (years 2 and 3 of the ECLIPSE
study), 1234 (67.7%) patients reported an exacerbation; of these,
Table 1 Baseline patient characteristics: first-year completers
versus first-year dropout
1st year
completers
N=1832
1st year
dropouts
N=306
Age, years 63.4 (7.0) 63.9 (7.8)
Male, n (%) 1199 (65.4) 195 (63.7)
Current smokers, n (%) 659 (36.0) 114 (37.3)
BMI, kg/m2† 26.0 (22.7–29.6) 25.6 (22.4–29.5)
FEV1, % predicted
a 48.7 (15.6)* 45.8 (16.1)
FEV1, L
a 1.4 (0.5)* 1.3 (0.5)
FVC, L a 3.1 (0.9)* 2.9 (1.0)
FEV1/FVC (%)
a 44.9 (11.5) 43.8 (11.6)
Exacerbations previous 12 months, n† 0.9 (1.2) 0.9 (1.2)
6MWD, mb,c 378 (119)** 324 (126)
mMRC dyspnoea score (%)d,e 1.6 (1.1)** 1.9 (1.1)
BODE index, pointsf,g 3.1 (2.1)** 3.8 (2.3)
CES-D score, pointsh,i 11.2 (9.3)** 13.2 (9.3)
FACIT score, pointsj,k 35.4 (10.6)** 33.1 (10.7)
SGRQ symptom score, pointsl 60.1 (21.5)** 64.8 (21.1)
SGRQ activity score, pointsm 61.8 (21.9)** 68.3 (20.9)
SGRQ impact score, pointsn 35.5 (19.3)** 39.8 (20.0)
SGRQ total score, pointso 47.6 (18.3)** 52.7 (18.2)
Values expressed as mean (SD), median (25%–75% percentile) or number of patients
(n), proportion (%).
*p≤0.05; **p≤0.001.
†Non-parametric tests were used for skewed data.
an=1828 (‘1st year completers’), bn=1791 (‘1st year completers’), cn=298 (‘1st year
dropout’), dn=1787 (‘1st year completers’), en=285 (‘1st year dropout’), fn=1743 (‘1st
year completers’), gn=292 (‘1st year dropout’); hn=1801 (‘1st year completers’),
in=297 (‘1st year dropout’); jn=1794 (‘1st year completers’), kn=293 (‘1st year
dropout’), ln=281 (‘1st year dropout’), mn=251 (‘1st year dropout’), nn=249 (‘1st year
dropout’), on=229 (‘1st year dropout’).
BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced
vital capacity; 6MWD, 6-minute walk distance; mMRC, modified Medical Research
Council dyspnoea scale; BODE, body mass index, airway obstruction, dyspnoea, and
exercise tolerance; CES-D, Center for Epidemiologic Studies Depression Scale; FACIT,
Functional Assessment of Chronic Illness Therapy fatigue scale; SGRQ, St George’s
Respiratory Questionnaire.
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hospitalisation occurred in 486 (26.7%) patients. There were 113
(6.2%) deaths during 2-year follow-up, with an average time to
death of 754 (183) days from baseline assessment.
Patients with a 1-year improvement had better survival than
those who deteriorated (HR=0.61, 95% CI 0.39 to 0.95,
p=0.027), similarly those who remained stable had better sur-
vival (HR=0.58, 95% CI 0.37 to 0.92, p=0.019 vs deterior-
ation; ﬁgure 1A and table 3). Patients who improved or
remained stable also had a lower likelihood of having a hospital-
isation (HR=0.72, 95% CI 0.58 to 0.90, p=0.004 improve-
ment vs deterioration; HR=0.77, 95% CI 0.62 to 0.96,
p=0.023 no change vs deterioration; ﬁgure 1B and table 3).
A similar observation was noted with risk of exacerbation
(HR=0.78, 95% CI 0.67 to 0.89, p<0.001 improvement vs
deterioration; HR=0.84, 95% CI 0.73 to 0.97, p=0.016 no
change vs deterioration; ﬁgure 1C and table 3). The association
between 1-year change in health status and exacerbation, hospi-
talisation and dying was affected by age and number of exacer-
bations and hospitalisations during year 1. Nevertheless,
patients with a 1-year deterioration in health status had worst
outcomes in most scenarios (see ﬁgure 1, online supplementary
ﬁgures E1–E3 and table E1). The results retrieved from the
SGRQ total score are comparable with the results retrieved
from the SGRQ impact domain scores (see online
supplementary Figure E4 and table E2).
DISCUSSION
This is the ﬁrst study exploring the association between changes
in health status and the likelihood of having an exacerbation,
hospitalisation and dying in a large cohort of patients with
COPD. Patients with a 1-year improvement or stable health
status had a lower likelihood of having an exacerbation, hospi-
talisation or dying compared with patients who worsened.
Recent studies have identiﬁed numerous determinants of
change in health status,12–14 but knowledge about the import-
ance of such changes is scarce. In the current study, patients
with a deterioration in health status during 1 year had a higher
chance of an exacerbation, hospitalisation or dying during 2
years of follow-up. These ﬁndings support the recommendation
by the GOLD committee to include the improvement of health
status as an objective in COPD management.15 As stated before,
‘health status measurement is a means of quantifying, in a stan-
dardised and objective manner, the impact of disease on patients’
daily life, health, and wellbeing. It is a process that is essentially
similar to a highly structured clinical history, although the end
product is not a clinical impression but an objective measurement
that can be used for scientiﬁc purposes. It is no more “soft” or
“touchy-feely” than any well taken clinical history’.16
The current study suggests a prognostic role for health status
measurement that may help professionals to identify patients at
increased risk of adverse health events.
The current study showed that the results retrieved from the
SGRQ total score are comparable with those retrieved from
the SGRQ impact domain score. This is not surprising since the
SGRQ impact domain score behaves in a similar way to the
total score whereas the SGRQ symptom domain score has been
identiﬁed as the weakest correlate with overall health. The
SGRQ impact domain covers aspects concerning social function-
ing and psychological disturbances related to the disease. It is
Table 2 Baseline patient characteristics
SGRQ total score
Whole group
(n=1832)
Improvement
(Δ≤−4 points)
(n=675)
No change
(Δ=−3.99 to 3.99)
(n=630)
Deterioration
(Δ≥4 points)
(n=527)
Age, years 63.4 (7.0) 63.0 (7.0) 63.6 (7.1) 63.6 (6.9)
Male, n (%) 1199 (65.4) 438 (64.9) 411 (65.2) 350 (66.4)
Current smokers, n (%) 659 (36.0) 258 (38.2)* 202 (32.1)** 199 (37.8)
BMI, kg/m2† 26.0 (22.7–29.6) 25.9 (22.9–29.3) 26.5 (23.2–29.9)** 25.6 (22.1–29.6)
FEV1, % predicted
a,b 48.7 (15.6) 48.8 (15.2) 49.3 (15.9) 47.7 (15.7)
FEV1, L
a,b 1.4 (0.5) 1.4 (0.5) 1.4 (0.6) 1.3 (0.5)
FVC, La,b 3.1 (0.9) 3.1 (0.9) 3.1 (0.9) 3.0 (0.9)
FEV1/FVC (%)
a,b 44.9 (11.5) 44.9 (11.4) 45.6 (11.8) 44.1 (11.4)
Exacerbations previous 12 months, n† 0.9 (1.2) 0.8 (1.2) 0.9 (1.3) 0.9 (1.2)
6MWD, mc,d,e 378 (119) 382 (112) 378 (127) 371 (118)
mMRC dyspnoea score (%)f,g,h,i 1.6 (1.1) 1.7 (1.0) 1.7 (1.1) 1.6 (1.1)
BODE index, pointsj,k,l,m 3.1 (2.1) 3.0 (1.9) 3.1 (2.2) 3.2 (2.1)
CES-D score, pointsn,o,p,q 11.2 (9.3) 11.7 (9.3) 10.9 (9.2) 10.7 (9.3)
FACIT score, pointsi,h,r 35.4 (10.6) 34.8 (10.5) 35.6 (11.0) 36.0 (10.3)
SGRQ symptom score, points 60.1 (21.5) 64.1 (20.4)*,** 58.5 (21.9) 56.7 (21.5)
SGRQ activity score, points 61.8 (21.9) 65.5 (19.6)*,** 60.3 (23.7) 58.8 (21.8)
SGRQ impact score, points 35.5 (19.3) 40.0 (18.8)*,** 34.7 (20.3)** 30.9 (17.4)
SGRQ total score, points 47.6 (18.3) 51.8 (16.9)*,** 46.4 (19.7)** 43.6 (17.1)
One-year change SGRQ total score, points −1.3 (10.7) −11.8 (7.5)*,** 0.3 (2.3)** 10.7 (5.9)
Values expressed as mean (SD), median (25–75% percentile) or number of patients (n), proportion (%).
*p≤0.05 versus ‘No change’; **p≤0.05 versus ‘Deterioration’.
†Non-parametric tests were used for skewed data.
an=1828 (‘whole group’), bn=671 (‘improvement’), cn=1791 (‘whole group’), dn=617 (‘no change’), en=512 (‘deterioration’), fn=1787 (whole group’), gn=658 (‘improvement’), hn=611
(‘no change’), in=518 (‘deterioration’), jn=1743 (‘whole group’), kn=641 (‘improvement’), ln=667 (‘no change’), mn=504 (‘deterioration’), nn=1801 (‘whole group’), on=598
(‘improvement’), pn=614 (‘no change’), qn=520 (‘deterioration’), rn=665 (‘improvement’).
BMI, body mass index; FACIT, Functional Assessment of Chronic Illness Therapy fatigue scale; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; 6MWD,
6-min walk distance; MRC, Medical Research Council dyspnoea scale; BODE, body mass index, airway obstruction, dyspnoea, and exercise tolerance; CES-D, Center for Epidemiologic
Studies Depression Scale; SGRQ, St George’s Respiratory Questionnaire.
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the broadest domain with the most items that correlates best
with outcomes in COPD.17 Thus, health status is rather a
measure of the impact of the disease and the illness perception
of the patient than a measure of general well-being. For
instance, a previous study showed that patients with a poor
health status were more likely to be referred to the respiratory
specialist.18 Furthermore, patients whose health status improved
had a decreased consultation and hospitalisation rate.19
Consequently, health status may be closely related to self-
management and coping strategies. Indeed, patients with COPD
speciﬁed coping as a relevant component of health status.20
Previously, psychological distress and difﬁculty in coping with
their disease has been shown to impact mortality in patients
with severe COPD.21 Therefore, self-regulation could signiﬁ-
cantly assist participants to control their individual symptoms
and avoid acute exacerbations.22 Consequently, a worsening in
health status may be associated with important health outcomes,
such as hospitalisation and death. The current study demon-
strates that patients’ perceptions and changes of patients’ per-
ceptions about their health as assessed by SGRQ can play a
meaningful role in COPD prognosis.
These data suggest that monitoring for trends in health status
over time are important, but they are conﬁned to health status
measured using the SGRQ, which is too complex for use in
routine practice. However there is already evidence that the
shorter instruments such as the COPD Assessment Test, which
were designed for routine use, can also predict exacerbations in
patients already known to be at high risk.23
Even in younger patients (age ≤64 years) whose health status
deteriorated during the ﬁrst year, there was a greater risk of
dying or an exacerbation compared with patients whose health
status remained stable or improved. Bentsen and colleagues24
recently showed that younger patients and those with higher
anxiety scores reported worse health status. The authors
explained this phenomenon by the fact that younger patients
are still learning how to cope with their disease and that older
patients experience functional impairment more often as a part
of getting older.24 In the current study, younger patients
reported signiﬁcantly higher Center for Epidemiologic Studies
Depression Scale scores (ie, more symptoms of depression) and
worse health status at baseline compared with older patients
(see online supplementary table E3). The current study under-
lines the importance to pay special attention to the health status
of younger patients with COPD and their perceptions of the
impact of the disease.
COPD as a leading cause of death is increasing25 and the eco-
nomic burden of the disease is substantial.26–28 Indeed, COPD
exacerbations requiring hospitalisation are a ‘major cost driver’28
that continue to increase.27 Consequently, prognostic measure-
ments for the progression of the disease are important.
Moreover, prevention and early treatment of exacerbations are
needed. The current study indicates a need for assessing health
status as a possible part of exacerbation prevention strategies.
Furthermore, the current study supports the interest in stabilising
or enhancing health status in patients with COPD. A previous
study showed that frequent exacerbations are related to poor
health status.29 Since the current study identiﬁed a decline in
health status as a contributing risk factor for getting an exacerba-
tion, even after stratiﬁcation for the exacerbation and hospitalisa-
tion frequency during year 1, it is important to interrupt this
vicious circle and intervene on time. Stabilising and/or improving
health status can be achieved by providing optimal pharmaco-
logical,30 medical/surgical31 and non-pharmacological treatment,
including pulmonary rehabilitation.32 Finally, the enhancement
of patient’s compliance with treatment is important since patients
who withdrew from treatment showed a more rapid decline in
health status.33 However, since health status shares causative
factors with other outcomes reﬂecting different processes, it is
important to recognise that treatments resulting in improved
health status will also have similar effects on other mechanisms.
Figure 1 Impact of 1-year change in disease-speciﬁc health status on
(A) mortality (n=1832), (B) hospitalisation (n=1823) and (C)
exacerbation (n=1823).
Table 3 HRs, accompanied with 95% CIs for the whole group
HR (95% CI)
Improvement vs
no change
No change vs
deterioration
Improvement vs
deterioration
SGRQ total score
Survival 1.05 (0.65 to 1.69) 0.58 (0.37 to 0.92) 0.61 (0.39 to 0.95)
Hospitalisation 0.94 (0.76 to 1.17) 0.77 (0.62 to 0.97) 0.72 (0.58 to 0.90)
Exacerbation 0.93 (0.82 to 1.07) 0.84 (0.73 to 0.97) 0.78 (0.67 to 0.89)
Bold printed numbers represent significant (p≤0.05) results.
SGRQ, St George’s Respiratory Questionnaire.
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Although the ECLIPSE study is a multicentre, longitudinal,
prospective 3-year study that included a large number of patients
worldwide, thus allowing an in-depth characterisation of the
COPD population, there are relevant limitations that should be
taken into account. First, the study consisted of a convenience
sample of secondary care patients. Patients were eligible if they
had moderate to very severe COPD, excluding patients with mild
airﬂow limitation (GOLD stage I). Furthermore, patients who
reported a better health status at baseline had a greater chance to
worsen during 1-year follow-up and vice versa. Consequently,
part of the effect of change in health status could be explained by
a statistical artefact such as regression to the mean;34 however,
that would not explain the association between change in health
status and the other outcomes. Moreover, there was no inter-
action between change in SGRQ score and baseline SGRQ score.
Finally, the current ﬁndings need to be interpreted in the light of
the number of comparisons that were made in the present
study.35 Nonetheless, multiple ﬁndings in the same direction,
rather than a single statistically signiﬁcant result, suggest that
these are not due to chance alone.
To conclude, ECLIPSE COPD subjects with a 1-year improve-
ment or stable health status had a lower likelihood of having an
exacerbation, hospitalisation or dying during 2-year follow-up
compared with those whose health status deteriorated. The
current study supports the concept of routine monitoring health
status of patients with COPD with the aim of improving or at
least stabilising their health status.
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